Skip to main content

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

 PHARMACOTHERAPY: 

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors (Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

5. a-GLUCOSIDASE INHIBITORS

  • Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States.

Mechanism of Action:

  • An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels.


Therapy:

As a monotherapy, a-glucosidase inhibitors primarily reduce post-prandial glucose excursions. 

Clinical Use:

FPG concentrations have been decreased by 40-50mg/dL and A1c levels are decreased by 0.3%-1%.

Adverse Effects:

  • High incidences of GI Upset such as Flatulence, abdominal discomfort, and diarrhea. 
  • GI effects occur as a result of intestinal bacteria in the distal gut metabolizing undigested carbohydrates and producing carbon dioxide and methane gas.

Contraindications:

Contraindicated in patients with;

  • short bowel syndrome
  • Inflammatory Bowel Disease
  • In patients with serum creatinine greater than 2mg/dL.


6. DIPEPTIDYL PEPTIDASE-4 INHIBITORS (GLIPTINS)

  • Drugs included mostly are Sitagliptin, Saxagliptin and Linagliptin.
  • These are approved as adjunct to diet and exercise to improve glycemic control in adults with T2DM.

Mechanism of Action:

  • These agents lower the blood glucose levels by inhibiting DPP-4; the enzyme that degrade endogenous GLP-1(Incretins). DPP-4 Inhibitors increase the amount of endogenous GLP-1.


Clinical Use:

  • Used primarily to decrease postprandial blood glucose levels.
  • Typical A1c reductions are 0.7-1%.

Adverse effects:

  • Headache
  • Nasopharyngitis
  • Hypoglycemia

Dose Adjustments:

Sitagliptin: Dosage adjustments for 50-25mg/day are recommended for patients with moderate and severe renal impairment, respectively.

Saxagliptin: should be dosed at 2.5mg/day with creatinine clearance less than 50ml/min or if strong CYP3A4/5 inhibitors are being used concomitantly.

Linagliptin: is a substrate of CYP3A4 is dosed at 5mg/day and requires no adjustment for renal or hepatic impairment.

Labels:

Comments

Post a Comment

Popular posts from this blog

General Mechanism of Actions of INSULIN.

GENERAL MECHANISM OF ACTION OF INSULIN AND RELATE HORMONES The body's main fuel is Glucose. Glucose is stored in the liver and muscles as Glycogen.  Excess glucose is stored in the adipose tissues which yield fatty acids via lipolysis. In the fasting state, free fatty acids supply much of the energy needs of the body except for the CNS which requires Glucose to function normally. Proteins can also be converted to glucose via gluconeogenesis. RELEASE OF INSULIN AND GLUCAGON Insulin and Glucagon are produced in the pancreas by the Islets of Langerhans . Beta cells   make up 70%-90% of the Islets and produce Insulin and Amylin while the a-cells   produce glucagon. The main function of insulin is to decrease blood glucose levels. Glucagon, along with other counter-regulatory hormones such as growth factor, cortisol, and Epinephrine, increases Blood glucose levels.  The opposing actions of Glucagon and Insulin along with other counter-regulatory hormones maintain a norma...
Post a Comment
Read more

Diabetes Mellitus: Its Goals Of Therapy!

  GOAL OF THERPY The goals of treatment of DM includes; Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications. Preserving beta cell function. Preventing acute complications from increased Blood glucosel level. Minimizing hypoglycemic episodes. Maintaining patient quality of life. --Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications. --A near normal blood glucose level can be achieved with appropriate patient education , lifestyle modification and medications . --Proper care of DM requires goal setting and assessment for glycemic control , self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure , and lipid levels , regular monitoring for the development of complications , dietary and exercise lifestyle modifications and proper medicatio...
Post a Comment
Read more